HIV-1 vaccine clinical trials: The Brazilian experience

Reviews in Medical Virology

Volumn 19, Issue 5, 2009, Pages 301-311

  Ersching, Jonatan ^a   Pinto, Aguinaldo R ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CP 1452; DENDRITIC CELL VACCINE; DNA VACCINE; ENVELOPE PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 15; LIVE VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEF PROTEIN; PLACEBO; PLASMID DNA; POL PROTEIN; UNCLASSIFIED DRUG; SUBUNIT VACCINE;

BRAZIL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FUNDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; VACCINATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; BRAZIL; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 70350743150     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.625     Document Type: Review

References (58)

1. UNAIDS/WHO. Report on the global HIV/AIDS epidemic 2008. UNAIDS: Geneva, 2008.
2. Ministério da Saú de. Boletim Epidemiológico - AIDS e DST. Ministério da Saú de: Brasília, 2007.
3. UNAIDS/WHO. Epidemiological Fact Sheet on HIV and AIDS. Brazil 2008 Update. UNAIDS: Geneva, 2008.
4. Stover J, Bollinger L, Hecht R, et al. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff 2007; 26: 1147-1158. DOI: 10.1377/hlthaff.26.4.1147
5. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455: 613-619. DOI: 10.1038/nature07352
6. Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med 2003; 3: 183-193.
7. IAVI. AIDS vaccine blueprint 2008: a challenge to the field, a roadmap for progress. International AIDS Vaccine Initiative, 2008.
8. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5: 233-236. DOI: 10.1038/ni0304-233 (Pubitemid 38332116)
9. Trials of Preventive Vaccines Worldwide. http:// www.avac.org/ [02 November 2008].
10. McMichael A, Mwau M, Hanke T. HIV T cell vaccines, the importance of clades. Vaccine 2002; 20: 1918-1921. DOI: 10.1016/S0264-410X(02)00067-1 (Pubitemid 34450787)
11. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Eng J Med 2007; 356: 2073-2081. DOI: 10.1056/NEJMra066267
12. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double blind, randomized, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893. DOI: 10.1016/S0140-6736(08)61591-3
13. McElrath JM, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372: 1894-1905. DOI: 10.1016/S0140-6736(08)61592-5
14. Baker BM, Block BL, Rothchild AC, et al. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009; 9: 55-69. DOI: 10.1517/ 14712590802571928
15. Carvalho-Silva DR, Santos FR, Rocha J, et al. The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet 2001; 68: 281-286.
16. Pimenta JR, Zuccherato LW, Debes AA, et al. Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 2006; 62: 190-195. DOI: 10.1159/000096872
17. Morgado MG, Barcellos C, Pina MF, et al. Human immunodeficiency virus/acquired immunodefi- ciency syndrome and tropical diseases: a Brazilian perspective. Mem Inst Oswaldo Cruz 2000; 95: 145-151. DOI: 10.1590/S0074- 02762000000700024
18. Júnior AB, Szwarcwald CL, Pascom ARP, et al. Trends in the AIDS epidemic in groups at highest risk in Brazil, 1980-2004. Cad Saude Publica 2009; 25: 727-737. DOI: 10.1590/S0102-311X2009000400003
19. Hemelaar J, Gouws E, Ghys PD, et al. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20: 13-23. DOI: 10.1097/01.aids.0000247564.73009.bc
20. Thomson MM, Nájera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 2005; 7: 210-224. (Pubitemid 43115953)
21. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis. 2004; 4: 397-413. DOI: 10.1016/S1473-3099(04)01056-4
22. Soares MA. Drug resistance differences among HIV types and subtypes: a growing problem. Future HIV Ther 2008; 2: 579-593. DOI:10.2217/17469600.2.6
23. Ministry of Health, National Secretary for Health Surveillance, Secretary of Science, Technology and Strategic Inputs. Brazilian HIV Vaccine Plan 2008-2012. Research, Development and Innovation. Ministry of Health: Brasilia, 2008.
24. IAVI report. http://www.iavireport.org/ [13 November 2008].
25. Gorse GJ, Keefer MC, Belshe RB, et al. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173: 330-339.
26. Lambert JS, Keefer M, Mulligan MJ, et al. A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001; 19: 3033-3042. DOI: 10.1016/S0264-410X(01)00051-2 (Pubitemid 32324030)
27. Kelleher AD, Emery S, Cunningham P, et al. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res Hum Retroviruses 1997; 13: 29-32. (Pubitemid 27002966)
28. ClinicalTrials.gov. http://www.clinicaltrials.gov/ [15 May 2009].
29. Schechter M. HIV vaccine evaluation center in Rio de Janeiro, Brazil. Vaccine 2002; 20: 1909-1911. DOI: 10.1016/S0264-410X(02)0065-8 (Pubitemid 34450785)
30. McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006; 20: 1481-1489. (Pubitemid 44100208)
31. Cleghorn F, Pape JW, Schechter M, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 canarypox vaccine (ALVAC-HIV vCP 1452) with or without boosting with MN rgp 120. J Acquir Immune Defic Syndr 2007; 46: 222-230. (Pubitemid 47482619)
32. Lu W, Arraes LC, Ferreira WT, et al. Therapeutic dendritic- cell vaccine for chronic HIV-1 infection. Nature 2004; 10: 1359-1365. DOI: 10.1038/nm1147 (Pubitemid 40022718)
33. The Community Advisory Board Bulletin. Vol.8, Issue 1 March/April 2007.
34. HIV Vaccine Trials Network. http://www.hvtn. org/ [05 December 2008].
35. HVTN Vaccines in Development. http://www.chi. ucsf.edu/ [14 November 2008].
36. The Community Advisory Board Bulletin. Vol.6, Issue 1: July/August 2003.
37. Tobery TW, Dubey SA, Anderson K, et al. A comparison of standart immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV type 1 gag vaccinated human subjects. AIDS Res Hum Retroviruses 2006; 22: 1081-1090. DOI: 10.1089/aid.2006.22.1081 (Pubitemid 44904257)
38. Harro C, Edupuganti S, Priddy F, et al. Safety and immunogenicity of adenovirus type 5 (Ad5) HIV-1 gag vaccines. 12th Conference on Retroviruses and Opportunistic Infections. Boston, US, 22-25 February 2005. Abstract G-115.
39. Robertson M, Kublin J, Leavitt R, et al. Safety review of Merck's adenovirus type 5 (Ad5) HIV vaccines in healthy adults. 12th Conference on Retroviruses and Opportunistic Infections. Boston, US, 22-25 February 2005. Abstract G-109.
40. The Step Study. http://www.stepstudies.com/ [10 November 2008].
41. National Institutes of Allergy and Infectious Diseases. http://www3.niaid.nih.gov/ [18 November 2008].
42. Wilson NA, Reed J, Napoe GS, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006; 80: 5875-5885. DOI: 10.1128/ JVI.00171-06 (Pubitemid 43849165)
43. Liang X, Casimiro DR, Schleif WA, et al. Vectored gag and env but not tat show efficacy against simian-human immunodeficiency virus 89.6p challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005; 79: 12321-12331. DOI:10.1128/ JVI.79.19.12321-12331.2005 (Pubitemid 41346094)
44. Hanke T. Step trial and HIV-1 vaccines inducing Tcell responses. Expert Rev Vaccines 2008; 7: 303-309. DOI: 10.1586/14760584.7.3.303
45. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008; 24: 2717-2725. DOI: 10.1084/jem.20081786/DC1
46. Cohen J. Thumbs down on expensive, hotly debated trial of NIH AIDS vaccine. Science 2008; 321: 472. DOI: 10.1126/science.321.5888.472
47. Programa Nacional de DST e AIDS. http:// www.aids.gov.br/ [20 December 2008].
48. Roberts L, Jasny B. HIV/AIDS:Money Matters. Science 2008; 321: 511. DOI: 10.1126/science.321.5888.511
49. WHO. Progress Report 2008. WHO Press: Geneva, 2008.
50. Prince AM, Reesink H, Pascual D, et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991; 7: 971-973.
51. Ruprecht RM. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol Biol 2009; 525: 559-566. DOI:10.1007/978-1-59745-554-1
52. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018. (Pubitemid 29189846)
53. Koff WC, Johnson PR, Watkins DI, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006; 7: 19-23. DOI: 10.1038/ni1296
54. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41: 1053-1056. DOI: 10.1086/433188 (Pubitemid 41368233)
55. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27: 406-416. DOI: 10.1016/j.immuni.2007.08.010
56. Choudhary SK, Vrisekoop N, Jansen CA, et al. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007; 81: 8838-8842. DOI: 10.1128/JVI.02663-06 (Pubitemid 47242858)
57. O'Connor GM, Holmes A, Mulcahy F, et al. Natural killer cells from long-term non-progressor HIV patients are characterized by altered phenotype and function. Clin Immunol 2007; 124: 277-283. DOI:10.1016/j.clim.2007.05.016 (Pubitemid 47247613)
58. Lehner T, Wang Y, Pido-Lopez J, et al. The emerging role of innate immunity in protection against HIV-1 infection. Vaccine 2008; 26: 2997-3001. DOI:10.1016/ j.vaccine.2007.11.060